Singapore National Eye Centre, Singapore; Singapore Eye Research Institute, Singapore.
Am J Ophthalmol. 2013 Aug;156(2):260-266.e2. doi: 10.1016/j.ajo.2013.03.020. Epub 2013 Apr 24.
To describe outcomes of corneal transplantation for irreversible corneal decompensation from corneal endotheliitis in Asian eyes.
Retrospective, observational case series.
We reviewed consecutive patients with corneal endotheliitis (32 eyes of 31 subjects) who underwent keratoplasty (January 1, 2008-December 1, 2009). All eyes had preoperative aqueous polymerase chain reaction (PCR) analysis for viruses, including cytomegalovirus (CMV). CMV-positive patients were treated preoperatively with topical corticosteroids and anti-CMV treatment (oral valganciclovir 900 mg twice daily, topical ganciclovir 0.15% 5 applications per day, for 6 weeks) with complete resolution of ocular inflammation, and quiescence for at least 6 months before corneal transplantation. Our main outcome measure was recurrence of endotheliitis within 1 year after corneal transplantation.
Five eyes were CMV positive; the remaining 27 eyes were negative for all viruses on PCR analysis. CMV-positive patients had a higher rate of recurrence of endotheliitis within 1 year after corneal transplantation, compared with CMV-negative eyes (60% vs 7.4%, P = .01). The CMV-positive eyes had recurrent endotheliitis at a median of 10 months (range 3-11 months) after corneal transplantation. After successful anti-CMV treatment, all 5 CMV-positive eyes then continued to have clear grafts for a median duration of 21 months (range 13-44 months).
Our study suggests that Asian patients with corneal endotheliitis may benefit from preoperative aqueous PCR analysis before corneal transplantation. Such patients were more likely to have a recurrence of endothelial inflammation if they were CMV positive preoperatively, despite successful anti-CMV treatment before surgery.
描述亚洲人因角膜内皮炎导致的不可逆转角膜失代偿行角膜移植的结果。
回顾性观察性病例系列研究。
我们回顾了 2008 年 1 月 1 日至 2009 年 12 月 1 日期间连续接受角膜移植术(32 只眼,31 例)的角膜内皮炎患者(32 只眼,31 例)。所有患者术前均行房水聚合酶链反应(PCR)分析病毒,包括巨细胞病毒(CMV)。CMV 阳性患者术前采用局部皮质类固醇和抗 CMV 治疗(口服缬更昔洛韦 900mg,每日 2 次,更昔洛韦 0.15%,每日 5 次,共 6 周),眼部炎症完全消退,且在角膜移植前至少稳定 6 个月。我们的主要观察指标是角膜移植术后 1 年内内皮炎的复发率。
5 只眼 CMV 阳性,27 只眼 PCR 分析均为其他病毒阴性。CMV 阳性患者角膜移植术后 1 年内内皮炎复发率高于 CMV 阴性患者(60%比 7.4%,P=0.01)。CMV 阳性眼在角膜移植后中位时间 10 个月(3-11 个月)时复发内皮炎。成功抗 CMV 治疗后,5 只 CMV 阳性眼均继续保持透明移植物,中位持续时间为 21 个月(13-44 个月)。
我们的研究表明,亚洲角膜内皮炎患者行角膜移植术前可能受益于房水 PCR 分析。此类患者如果术前 CMV 阳性,即使术前接受了成功的抗 CMV 治疗,术后仍更有可能发生内皮炎症复发。